share_log

藥明康德：翌日披露報表

WUXI APPTEC: Next Day Disclosure Return

香港交易所 ·  Mar 21 06:09
Summary by Moomoo AI
無錫藥明康德新藥開發股份有限公司於2024年3月8日至21日進行了一系列股份回購活動，並於2024年3月21日根據股份期權計劃行使期權發行新股。根據公司提交的翌日披露報表，公司在上述期間內共回購了2,546,179,158股A類普通股，並於3月21日行使期權發行了3,400股A類普通股。股份回購的交易價格介於RMB 50.16至RMB 57.32之間，而行使期權的發行價為RMB 38.62，均根據當時的市場價格進行。公司確認，所有交易均已獲得董事會的正式授權批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
無錫藥明康德新藥開發股份有限公司於2024年3月8日至21日進行了一系列股份回購活動，並於2024年3月21日根據股份期權計劃行使期權發行新股。根據公司提交的翌日披露報表，公司在上述期間內共回購了2,546,179,158股A類普通股，並於3月21日行使期權發行了3,400股A類普通股。股份回購的交易價格介於RMB 50.16至RMB 57.32之間，而行使期權的發行價為RMB 38.62，均根據當時的市場價格進行。公司確認，所有交易均已獲得董事會的正式授權批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted a series of share repurchase activities from March 8 to 21, 2024, and issued new shares under the share option plan on March 21, 2024. According to the Company's Next Day Disclosure Report filed by the Company, the Company repurchased a total of 2,546,179,158 shares of Class A Ordinary Shares during the above period and issued an option to exercise 3,400 shares of Class A Ordinary Shares on March 21. The share repurchase price is between RMB 50.16 and RMB 57.32 and the option issue price is RMB 38.62, based on the market price at the time. The Company confirms that all transactions have been formally approved by the Board of Directors and comply with the relevant requirements of the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited.
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted a series of share repurchase activities from March 8 to 21, 2024, and issued new shares under the share option plan on March 21, 2024. According to the Company's Next Day Disclosure Report filed by the Company, the Company repurchased a total of 2,546,179,158 shares of Class A Ordinary Shares during the above period and issued an option to exercise 3,400 shares of Class A Ordinary Shares on March 21. The share repurchase price is between RMB 50.16 and RMB 57.32 and the option issue price is RMB 38.62, based on the market price at the time. The Company confirms that all transactions have been formally approved by the Board of Directors and comply with the relevant requirements of the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more